文献速递慢性肾脏病急性肾损伤

口服抗凝药治疗心房颤动患者的心肾结局

Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
PubMed 文献 · Am J Kidney Dis · 2022-10-05

本研究为回顾性队列研究,纳入2011-2018年瑞典斯德哥尔摩肌酐测量(SCREAM)项目中32,699例非瓣膜性心房颤动患者,56%起始使用直接口服抗凝药(DOAC)。与维生素K拮抗剂(VKA)相比,DOAC与较低的慢性肾脏病(CKD)进展、急性肾损伤(AKI)和大出血风险相关,而卒中/系统性栓塞复合终点和死亡风险相似。

要点

  • DOAC与VKA相比,CKD进展风险较低(HR 0.87)。
  • DOAC与VKA相比,AKI风险较低(HR 0.88)。
  • DOAC与VKA相比,大出血风险较低(HR 0.77),卒中/系统性栓塞和死亡风险相似。

核心结论

  • 在常规临床实践中,非瓣膜性AF患者使用DOAC与VKA相比,CKD进展、AKI和大出血风险较低,而卒中、系统性栓塞或死亡复合终点风险相似。

研究设计与样本

  • 回顾性队列研究,纳入瑞典斯德哥尔摩肌酐测量(SCREAM)项目中2011-2018年诊断为非瓣膜性AF的患者32,699例,56%起始使用DOAC,中位随访3.8年。

主要发现

  • DOAC vs VKA的CKD进展调整HR为0.87(95% CI 0.78-0.98),AKI调整HR为0.88(95% CI 0.80-0.97)。
  • DOAC vs VKA的大出血HR为0.77(95% CI 0.67-0.89),卒中/系统性栓塞复合终点HR为0.93(95% CI 0.78-1.11),死亡HR为1.04(95% CI 0.95-1.14)。
  • 中位年龄75岁,45%为女性,27%的患者eGFR<60mL/min/1.73m2。

局限性

  • 原文报告局限性包括:缺少治疗范围内时间和治疗剂量的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Direct oral anticoagulants (DOACs) have progressively replaced vitamin K antagonists (VKAs) for stroke prevention in patients with nonvalvular atrial fibrillation (AF). DOACs cause fewer bleeding complications, but their other advantages, particularly related to kidney outcomes, remain inconclusive. We studied the risks of chronic kidney disease (CKD) progression and acute kidney injury (AKI) after DOAC and VKA administration for nonvalvular AF. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Cohort study of Swedish patients enrolled in the Stockholm Creatinine Measurements (SCREAM) project with a diagnosis of nonvalvular AF during 2011-2018. EXPOSURE: Initiation of DOAC or VKA treatment. OUTCOME: Primary outcomes were CKD progression (composite of >30% estimated glomerular filtration rate [eGFR] decline and kidney failure) and AKI (by diagnosis or KDIGO-defined transient creatinine elevations). Secondary outcomes were death, major bleeding, and the composite of stroke and systemic embolism. ANALYTICAL APPROACH: Propensity score weighted Cox regression was used to balance 50 baseline confounders. Sensitivity analyses included falsification end points, subgroups, and estimation of per-protocol effects. RESULTS: We included 32,699 patients (56% initiated DOAC) who were observed for a median of 3.8 years. Their median age was 75 years, 45% were women, and 27% had an eGFR <60mL/min/1.73m2. The adjusted HRs for DOAC versus VKA were 0.87 (95% CI, 0.78-0.98) for the risk of CKD progression and 0.88 (95% CI, 0.80-0.97) for AKI. HRs were 0.77 (95% CI, 0.67-0.89) for major bleeding, 0.93 (95% CI, 0.78-1.11) for the composite of stroke and systemic embolism, and 1.04 (95% CI, 0.95-1.14) for death. The results were similar across subgroups of age, sex, and baseline eGFR when restricting to patients at high risk for thromboembolic events and when censoring follow up at treatment discontinuation or change in type of anticoagulation. LIMITATIONS: Missing information on time in therapeutic range and treatment dosages. CONCLUSIONS: Among patients with nonvalvular AF treated in routine clinical practice compared with VKA use, DOAC use was associated with a lower risk of CKD progression, AKI, and major bleeding but a similar risk of the composite of stroke, systemic embolism, or death.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Trevisan M, Hjemdahl P, Clase CM, et al. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. Am J Kidney Dis. 2022. PMID: 36208798. doi:10.1053/j.ajkd.2022.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。